FDA clears Medtronic Hugo robot for general surgery, about 3.5 million U.S. procedures a year

Medtronic said on Nov. 17 that the FDA cleared its Hugo robotic-assisted surgery system for general surgery. The expanded 510(k) covers all upper abdominal general surgical procedures, including gallbladder removal (cholecystectomy), Roux-en-Y gastric bypass, ventral hernia and small bowel resection, plus inguinal hernia repair and appendectomy. Medtronic estimates those procedures account for about 3.5 million U.S. surgeries a year, more than half of all U.S. soft-tissue procedures. Hugo's U.S. label previously covered only urology, cleared in December 2025. FDA's 510(k) database lists the new clearance as K261444, received May 1, 2026 and decided Nov. 13, four days before the announcement. A separate gynecology application remains under FDA review, MassDevice reports. Medtronic says Hugo is on track to pass 50,000 cumulative procedures worldwide by the end of its fiscal year in April 2027, with about 250 installed systems expected, per MassDevice. Pricing was not disclosed.
Servospace take: Hugo now has the label to compete where da Vinci makes its volume, but it starts about 48 times smaller
Servospace analysis: general surgery is where U.S. robotic surgery volume is, and until this clearance Hugo could not compete for it in the U.S. The gap is still enormous. Intuitive Surgical reported 12,094 da Vinci systems installed worldwide as of Sept. 30, 2026, 6,807 of them in the United States, and about 906,000 da Vinci procedures in the third quarter of 2026 alone. Medtronic's own targets, about 250 installed Hugo systems and 50,000 cumulative procedures by April 2027, put Hugo's installed base at roughly 1/48th of da Vinci's worldwide and its lifetime procedure count at about 1/18th of a single quarter of da Vinci cases (Servospace arithmetic on company figures). Medtronic's pitch is not raw scale but fit: a modular design that lets teams use only the robotic arms a case needs, an open console, and familiar Medtronic instruments such as the LigaSure RAS Maryland vessel sealer. The FDA timeline matters too: 196 days from receipt to decision for this filing, versus 268 days for Hugo's first U.S. clearance (received March 10, decided Dec. 3, 2025), per FDA 510(k) records. Watch for U.S. hospital placements and pricing, neither disclosed, and the pending gynecology decision.
More on surgical robots.
Sources
- Medtronic via PR Newswire (Nov. 17, 2026): FDA clearance of general surgery procedures for the Hugo RAS system (procedures covered, about 3.5 million U.S. surgeries a year, growth more than 2x market, 50,000 procedures by fiscal year end)
- FDA 510(k) database: K261444, Hugo RAS System, Covidien LLC (received May 1, 2026; decision Nov. 13, 2026; substantially equivalent)
- FDA 510(k) database: K250725, Hugo RAS System urology clearance (received March 10, 2025; decision Dec. 3, 2025)
- MassDevice (Nov. 17, 2026): Medtronic's Hugo robot claims long-awaited FDA general surgery clearance (gynecology application still under review; about 250 installed systems expected by fiscal year end)
- Intuitive Surgical (Oct. 2026): third quarter 2026 earnings (12,094 da Vinci systems installed as of Sept. 30, 2026)
- Intuitive Surgical Q3 2026 financial data tables (906,000 da Vinci procedures in Q3 2026)
- Intuitive Surgical Q3 2026 investor presentation (6,807 da Vinci systems installed in the United States)
New to robots? Read our guide: How robots work: a beginner's guide.
Summarized by Servospace from the sources above, drafted with AI help and checked against those sources before publishing. Claims are the companies' or outlets' unless we say otherwise. How we work.